Literature DB >> 10146982

Cost-effectiveness analysis: obstacles to standardisation and its use in regulating pharmaceuticals.

B R Luce.   

Abstract

Mesh：

Year:  1993        PMID： 10146982     DOI： 10.2165/00019053-199303010-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  24 in total

1.  Cost-effectiveness guidelines for reimbursement of pharmaceuticals: is economic evaluation ready for its enhanced status?

Authors:  M Drummond
Journal:  Health Econ       Date:  1992-07       Impact factor: 3.046

2.  Discounting and health benefits: another perspective.

Authors:  J Cairns
Journal:  Health Econ       Date:  1992-04       Impact factor: 3.046

3.  Discounting of health benefits in the pharmacoeconomic analysis of drug therapies: an issue for debate?

Authors:  D Coyle; K Tolley
Journal:  Pharmacoeconomics       Date:  1992-08       Impact factor: 4.981

4.  Economic evaluation of pharmaceuticals: science or marketing?

Authors:  M F Drummond
Journal:  Pharmacoeconomics       Date:  1992-01       Impact factor: 4.981

Review 5.  Generic and disease-specific measures in assessing health status and quality of life.

Authors:  D L Patrick; R A Deyo
Journal:  Med Care       Date:  1989-03       Impact factor: 2.983

6.  Health-related quality of life assessment and the pharmaceutical industry.

Authors:  D A Revicki; M Rothman; B Luce
Journal:  Pharmacoeconomics       Date:  1992-06       Impact factor: 4.981

Review 7.  Clinical economics. A guide to the economic analysis of clinical practices.

Authors:  J M Eisenberg
Journal:  JAMA       Date:  1989-11-24       Impact factor: 56.272

8.  Public-health rounds at the Harvard School of Public Health. Allocation of resources to manage hypertension.

Authors:  W B Stason; M C Weinstein
Journal:  N Engl J Med       Date:  1977-03-31       Impact factor: 91.245

9.  Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension.

Authors:  J T Edelson; M C Weinstein; A N Tosteson; L Williams; T H Lee; L Goldman
Journal:  JAMA       Date:  1990-01-19       Impact factor: 56.272

10.  Cost effectiveness of vaccination against pneumococcal pneumonia.

Authors:  J S Willems; C R Sanders; M A Riddiough; J C Bell
Journal:  N Engl J Med       Date:  1980-09-04       Impact factor: 91.245
View more
  5 in total

Review 1.  Why training is the key to successful guideline implementation.

Authors:  A D Paltiel; P J Neumann
Journal:  Pharmacoeconomics       Date:  1997-09       Impact factor: 4.981

2.  Strategic use of pharmacoeconomic research in early drug development and global pricing.

Authors:  K Clemens; L P Garrison; A Jones; F Macdonald
Journal:  Pharmacoeconomics       Date:  1993-11       Impact factor: 4.981

Review 3.  Cost effectiveness of smoking-cessation therapies. Interpretation of the evidence-and implications for coverage.

Authors:  K E Warner
Journal:  Pharmacoeconomics       Date:  1997-06       Impact factor: 4.981

4.  Methodological and conduct principles for pharmacoeconomic research. Pharmaceutical Research and Manufacturers of America.

Authors:  K Clemens; R Townsend; F Luscombe; J Mauskopf; J Osterhaus; J Bobula
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981

5.  A comprehensive review of official discount rates in guidelines of health economic evaluations over time: the trends and roots.

Authors:  Elahe Khorasani; Majid Davari; Abbas Kebriaeezadeh; Farshad Fatemi; Ali Akbari Sari; Vida Varahrami
Journal:  Eur J Health Econ       Date:  2022-03-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.